文献速递免疫规划传染病防控与疫情报告

2017/18季西班牙瓦伦西亚地区60岁及以上住院成人流感疫苗效果评估

Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season.
PubMed 文献 · Euro Surveill · 2019-01-01

本研究在西班牙瓦伦西亚医院监测网络内采用检测阴性设计,评估2017/18季三价流感疫苗对60岁及以上住院成人的保护效果。总体疫苗效果为9.9%(95%CI:-15.5至29.6%),对A(H1N1)pdm09为48.3%(95%CI:13.5%至69.1%),对A(H3N2)为-29.9%(95%CI:-79.1%至5.8%),对B/Yamagata为25.7%(95%CI:-8.8%至49.3%)。既往接种对B/Yamagata和重复接种对A(H1N1)pdm09显示保护作用。

要点

  • 2017/18季流感疫苗对60岁及以上住院成人总体保护效果低,为9.9%。
  • 疫苗对A(H1N1)pdm09株效果为48.3%,对A(H3N2)株为-29.9%。
  • 既往接种对未当前季接种者的B/Yamagata保护效果为50.2%。

核心结论

  • 2017/18季流感疫苗对60岁及以上住院成人总体效果低,但既往接种对A(H1N1)pdm09和B/Yamagata lineage有保护作用。

研究设计与样本

  • 多中心前瞻性观察性研究,基于西班牙瓦伦西亚医院流感与呼吸道病毒疾病监测网络(VAHNSI),采用检测阴性设计,对象为60岁及以上住院成人。

主要发现

  • 总体2017/18流感疫苗效果为9.9%(95%CI:-15.5至29.6%)。
  • 对A(H1N1)pdm09效果为48.3%(95%CI:13.5%至69.1%),对A(H3N2)为-29.9%(95%CI:-79.1%至5.8%),对B/Yamagata为25.7%(95%CI:-8.8%至49.3%)。
  • 佐剂疫苗总体效果为10.0%(95%CI:-24.4%至34.9%),非佐剂疫苗为7.8%(95%CI:-23.1%至31.0%)。
  • 当前季未接种者中,既往接种对B/Yamagata保护效果为50.2%(95%CI:2.3%至74.6%)。
  • 重复接种对A(H1N1)pdm09效果为46.4%(95%CI:6.8%至69.2%)。

临床怎么用

  • 应关注老年人流感疫苗效果的年际变化,并考虑既往接种史对当前季保护作用的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IntroductionInfluenza immunisation is recommended for elderly people each season. The influenza vaccine effectiveness (IVE) varies annually due to influenza viruses evolving and the vaccine composition.AimTo estimate, in inpatients ≥ 60 years old, the 2017/18 trivalent IVE, overall, by vaccine type and by strain. The impact of vaccination in any of the two previous seasons (2016/17 and 2015/16) on current (2017/18) IVE was also explored.MethodsThis was a multicentre prospective observational study within the Valencia Hospital Surveillance Network for the Study of Influenza and Respiratory Viruses Disease (VAHNSI, Spain). The test-negative design was applied taking laboratory-confirmed influenza as outcome and vaccination status as main exposure. Information about potential confounders was obtained from clinical registries and/or by interviewing patients; vaccine information was only ascertained by registries.ResultsOverall, 2017/18 IVE was 9.9% (95% CI: -15.5 to 29.6%), and specifically, 48.3% (95% CI: 13.5% to 69.1%), -29.9% (95% CI: -79.1% to 5.8%) and 25.7% (95% CI: -8.8% to 49.3%) against A(H1N1)pdm09, A(H3N2) and B/Yamagata lineage, respectively. For the adjuvanted and non-adjuvanted vaccines, overall IVE was 10.0% (95% CI: -24.4% to 34.9%) and 7.8% (95% CI: -23.1% to 31.0%) respectively. Prior vaccination significantly protected against influenza B/Yamagata lineage (IVE: 50.2%; 95% CI: 2.3% to 74.6%) in patients not vaccinated in the current season. For those repeatedly vaccinated against influenza A(H1N1)pdm09, IVE was 46.4% (95% CI: 6.8% to 69.2%).ConclusionOur data revealed low vaccine effectiveness against influenza in hospitalised patients ≥60 years old in 2017/18. Prior vaccination protected against influenza A(H1N1)pdm09 and B/Yamagata-lineage.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Mira-Iglesias A, López-Labrador FX, Baselga-Moreno V, et al. Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season. Euro Surveill. 2019. PMID: 31387672. doi:10.2807/1560-7917.ES.2019.24.31.1800461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。